[Form 4] Apogee Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Apogee Therapeutics director Jennifer A. Fox received a stock option grant on June 17, 2025. The derivative security details include:

• Right to purchase 14,461 shares of common stock
• Exercise price set at $41.66 per share
• Options will vest in full on the one-year anniversary of the grant date (June 17, 2026)
• Expiration date is June 17, 2035
• Total grant value at $0.00 cost to the director

The vesting is contingent upon Fox's continued service with Apogee Therapeutics. The Form 4 was filed through an attorney-in-fact, Matthew Batters, on June 20, 2025. This equity compensation grant aligns with standard director compensation practices and creates long-term alignment with shareholder interests.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Jennifer A.

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$41.66	06/17/2025		A		14,461		(1)	06/17/2035	Common Stock	14,461	$0.00	14,461	D

Explanation of Responses:

1. This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

	/s/ Matthew Batters, as attorney-in-fact for Jennifer Fox	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did Jennifer Fox receive from APGE on June 17, 2025?

Jennifer Fox received stock options to purchase 14,461 shares of APGE common stock at an exercise price of $41.66 per share. These options were granted on June 17, 2025, and will expire on June 17, 2035.

When do Jennifer Fox's APGE stock options vest?

The stock options will vest on the one-year anniversary of the grant date (June 17, 2026), subject to Jennifer Fox's continued service to Apogee Therapeutics.

What is Jennifer Fox's role at APGE?

According to the Form 4 filing, Jennifer Fox serves as a Director on the Board of Apogee Therapeutics, Inc. (APGE).

What was the total value of stock options granted to APGE director Jennifer Fox?

Jennifer Fox was granted options to purchase 14,461 shares at an exercise price of $41.66 per share. The options were reported with a price of $0.00 as they were granted as compensation, not purchased.

When did Jennifer Fox file the Form 4 for her APGE stock option grant?

The Form 4 was filed on June 20, 2025, reporting the stock option grant that occurred on June 17, 2025. The form was signed by Matthew Batters as attorney-in-fact for Jennifer Fox.